- Home
- BGI vs SABS Comparison
BGI vs SABS Comparison
Compare BGI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- SABS
- Stock Information
- Founded
- BGI 1879
- SABS 2014
- Country
- BGI Canada
- SABS United States
- Employees
- BGI N/A
- SABS N/A
- Industry
- BGI
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- SABS Health Care
- Exchange
- BGI Nasdaq
- SABS Nasdaq
- Market Cap
- BGI 15.9M
- SABS 15.8M
- IPO Year
- BGI 2005
- SABS N/A
- Fundamental
- Price
- BGI $0.84
- SABS $2.28
- Analyst Decision
- BGI
- SABS Strong Buy
- Analyst Count
- BGI 0
- SABS 5
- Target Price
- BGI N/A
- SABS $10.00
- AVG Volume (30 Days)
- BGI 201.0K
- SABS 85.9K
- Earning Date
- BGI 07-25-2025
- SABS 11-05-2025
- Dividend Yield
- BGI N/A
- SABS N/A
- EPS Growth
- BGI N/A
- SABS N/A
- EPS
- BGI N/A
- SABS N/A
- Revenue
- BGI $124,446,731.00
- SABS $114,698.00
- Revenue This Year
- BGI N/A
- SABS N/A
- Revenue Next Year
- BGI N/A
- SABS N/A
- P/E Ratio
- BGI N/A
- SABS N/A
- Revenue Growth
- BGI N/A
- SABS N/A
- 52 Week Low
- BGI $0.56
- SABS $1.00
- 52 Week High
- BGI $2.95
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- BGI 65.04
- SABS 54.42
- Support Level
- BGI $0.64
- SABS $2.03
- Resistance Level
- BGI $1.07
- SABS $2.34
- Average True Range (ATR)
- BGI 0.08
- SABS 0.12
- MACD
- BGI 0.02
- SABS 0.02
- Stochastic Oscillator
- BGI 46.53
- SABS 84.00
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.